Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of MIT-001 SC/IV in Healthy Subjects
NCT05389696Phase 1Completed
- Sponsor
- MitoImmune Therapeutics
- Start
- May 2022
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LC28-0126 in oral mucositis (OM) (5 arms), sponsored by MitoImmune Therapeutics. Primary endpoints: Maximum Plasma Concentration, Area Under the Concentration-Time Curve from Time Zero to Last Quantifiable Concentration and 13 more. Started May 2022; status: completed.
02
Drugs
LC28-0126
03
Conditions
oral mucositis (OM)
Beyond the preview
Go deeper on NCT05389696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05389696.